Neurocrine plots 2024 filing for rare disease drug after 'solid' PhIII win
Neurocrine’s lead neuroendocrinology program has passed its first Phase III test, setting up a potential FDA filing in 2024.
The San Diego biotech saw its shares $NBIX go up almost 7% to $117.10 Tuesday on the heels of the announcement that crinecerfont met primary and key secondary endpoints in the Phase III CAHtalyst trial. The trial enrolled 182 adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) — making it the largest ever interventional trial conducted in this rare disease, according to the principal investigator.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.